{"title":"Ovarian Cancer","description":null,"products":[{"product_id":"pholorla-100-lorlatinib","title":"OLADX 50 (Olaparib)","description":"\u003ch2\u003eAbout Olaparib\u003c\/h2\u003e\u003cp\u003eOlaparib is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\u003c\/p\u003e\u003cp\u003eOlaparib was approved by the FDA due to its objective response rate and response duration. Further of this indication\u003c\/p\u003e\u003cp\u003eApproval depends on the results of clinical benefit in confirmatory clinical trials.\u003c\/p\u003e\u003ch2\u003eDose and administration method\u003c\/h2\u003e\u003col\u003e\u003cli\u003eMethod of administration\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\n\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\n\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\n\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\n\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\n\u003c\/ul\u003e\u003col start=\"2\"\u003e\u003cli\u003eDosage specifications\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\u003c\/ul\u003e\u003col start=\"3\"\u003e\u003cli\u003eContraindications: None.\u003c\/li\u003e\u003c\/ol\u003e\u003ch2\u003eWarnings and Precautions\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\n\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\n\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAdverse reactions\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\n\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eStorage method\u003c\/h2\u003e\u003cp\u003eStore between 20-25°C.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797945872427,"sku":"RL3020240925","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-09-2018.jpg?v=1787022064"},{"product_id":"olieni-olaparib-50mg-2","title":"Olieni 50 (Olaparib)","description":" \r\n\u003cdiv class=\"woocommerce-product-details__short-description\"\u003e\r\n\r\n\u003cstrong\u003eIndications\u003c\/strong\u003e\r\n\r\nOlieni is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\r\n\r\nOlieni was approved by the FDA due to its objective response rate and response duration. Further of this indication\r\n\r\nApproval depends on the results of clinical benefit in confirmatory clinical trials.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cstrong\u003eDose and administration method\u003c\/strong\u003e\r\n\u003col\u003e\r\n \t\u003cli\u003eMethod of administration\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\r\n \t\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\r\n \t\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\r\n \t\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"2\"\u003e\r\n \t\u003cli\u003eDosage specifications\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003col start=\"3\"\u003e\r\n \t\u003cli\u003eContraindications: None.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cstrong\u003eWarnings and Precautions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\r\n \t\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\r\n \t\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdverse reactions\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\r\n \t\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eStorage method\u003c\/strong\u003e\r\n\r\nStore between 20-25°C.\r\n\r\n\u003c\/div\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947478059,"sku":"RL1420230901255","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1655264792-96bfa0933e18e60.jpg?v=1787022095"},{"product_id":"olieni-olaparib-100mg","title":"Olieni 100 (Olaparib)","description":" \r\n\u003ch3\u003e\u003cstrong\u003eIndications\u003c\/strong\u003e\u003c\/h3\u003e\r\nOlaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedical uses\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.\r\n\r\nWhy is this medication prescribed?\r\nOlaparib tablets are used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib tablets are also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. Olaparib tablets are also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib tablets and capsules are also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedicine usage\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib comes as a tablet or a capsule to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the tablet or capsule whole; do not crush chew, divide, or dissolve them.\r\n\r\nOlaparib is available as a tablet and as a capsule. The tablets and capsules contain different amounts of olaparib and should not be substituted for one another. Talk to your doctor or pharmacist if you have any questions about the tablet and capsule preparations.\r\n\r\nYour doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.\r\n\r\nYour doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm085729.htm) to obtain the Medication Guide.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eOther uses for this medicine\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003eside effects\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\r\nnausea\r\nvomiting\r\ndiarrhea\r\nconstipation\r\nheartburn\r\nheadache\r\ndecreased appetite\r\nmuscle, joint, or back pain\r\nfatigue\r\nstomach pain or discomfort\r\ntaste changes\r\nmouth pain or sores\r\nanxiety\r\ndepression\r\ndry skin\r\nitching\r\nrash\r\ndifficulty falling asleep or staying asleep","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947543595,"sku":"RL1420230901169","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663225716-df2184f4b46de3d.png?v=1787022096"},{"product_id":"nizela-niraparib-2","title":"Nizela (Niraparib)","description":"\u003cp\u003eNiraparib is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer.It is taken by mouth. It is a PARP inhibitor.\u003c\/p\u003e\n\n\u003cp\u003eThe most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping), headache, lack of appetite, diarrhea, dyspnea (difficulty breathing), hypertension (high blood pressure), back pain, dizziness, cough, joint pain, hot flushes and decrease in white blood cells.\u003c\/p\u003e\n\n\u003cp\u003eNiraparib was approved for medical use in the United States and in the European Union in 2017.\u003c\/p\u003e\n\n\u003cp\u003eMedical uses\u003cbr\u003e\nNiraparib is indicated for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn October 2019, the indication for niraparib was expanded to include people with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn April 2020, the indication for niraparib was expanded to include the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn the European Union, niraparib is indicated: as monotherapy for the maintenance treatment of adults with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; and as monotherapy for the maintenance treatment of adults with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.\u003c\/p\u003e\n\n\u003cp\u003eWhy is this medication prescribed?\u003cbr\u003e\nNiraparib is used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the stomach) cancer in people who have completely responded or partially responded to other chemotherapy medication(s). It is also used to treat certain types of ovarian, fallopian tube, or peritoneal cancer when the cancer has gotten worse after 3 or more chemotherapy treatments. Niraparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eHow should this medicine be used?\u003cbr\u003e\nNiraparib comes as a capsule to take by mouth once daily. Take niraparib at around the same time every day with or without food. If you experience nausea after taking niraparib, take it once daily at bedtime. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take niraparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\n\n\u003cp\u003eSwallow the capsules whole; do not open, chew, or dissolve them.\u003c\/p\u003e\n\n\u003cp\u003eIf you vomit after taking niraparib, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\n\n\u003cp\u003eYour doctor may decrease your dose of niraparib, or permanently or temporarily stop your treatment, if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with niraparib.\u003c\/p\u003e\n\n\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e\n\n\u003cp\u003eOther uses for this medicine\u003cbr\u003e\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\u003c\/p\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797947609131,"sku":"RL1420230901845","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1663226207-6a81a10cdb86766.png?v=1787022098"},{"product_id":"olieni-olaparib-150mg-2","title":"Olieni 150 (Olaparib)","description":"\u003ch3\u003e\u003cstrong\u003eIndications\u003c\/strong\u003e\u003c\/h3\u003e\r\nOlaparib is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedical uses\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.\r\n\r\nWhy is this medication prescribed?\r\nOlaparib tablets are used to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib tablets are also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. Olaparib tablets are also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib tablets and capsules are also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib tablets are also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eMedicine usage\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib comes as a tablet or a capsule to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\r\n\r\nSwallow the tablet or capsule whole; do not crush chew, divide, or dissolve them.\r\n\r\nOlaparib is available as a tablet and as a capsule. The tablets and capsules contain different amounts of olaparib and should not be substituted for one another. Talk to your doctor or pharmacist if you have any questions about the tablet and capsule preparations.\r\n\r\nYour doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.\r\n\r\nYour doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm085729.htm) to obtain the Medication Guide.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch3\u003eOther uses for this medicine\u003c\/h3\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis medication may be prescribed for other uses; ask your doctor or pharmacist for more information.\r\n\r\n\u003chr\u003e\r\n\r\n\u003cul\u003e\r\n \t\u003cli\u003eside effects\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOlaparib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:\r\nnausea\r\nvomiting\r\ndiarrhea\r\nconstipation\r\nheartburn\r\nheadache\r\ndecreased appetite\r\nmuscle, joint, or back pain\r\nfatigue\r\nstomach pain or discomfort\r\ntaste changes\r\nmouth pain or sores\r\nanxiety\r\ndepression\r\ndry skin\r\nitching\r\nrash\r\ndifficulty falling asleep or staying asleep\r\npain urinating.","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797948559403,"sku":"RL1420230901238","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/1653881111-0cec2b187d0d386.jpg?v=1787022117"},{"product_id":"avzivi-bevacizumab","title":"Avzivi (Bevacizumab)","description":"\u003cp\u003eAvzivi® (Bevacizumab-tnjn)  sold under the brand name POBEVCY (普贝希) in China, is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. \u003c\/p\u003e\u003cp\u003eDec 7, 2023，The FDA has approved the fifth bevacizumab biosimilar, Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) for the treatment of several types of cancer. Avzivi\u003csup\u003e®\u003c\/sup\u003e (BAT1706) is Bio-Thera Solutions’ second FDA approved product in the United States. Avzivi\u003csup\u003e®\u003c\/sup\u003e is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.\u003c\/p\u003e","brand":"Bio-Thera Solutions, China","offers":[{"title":"Default Title","offer_id":44797952360491,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2233.png?v=1787022174"},{"product_id":"generic-olaparib-oladx-150","title":"OLADX 150 (Olaparib)","description":"\u003ch2\u003e\u003cspan id=\"About_Olaparib\"\u003eAbout Olaparib\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eOlaparib is a poly (ADP ribose) polymerase (PARP) inhibitor, at least before monotherapy Germline BRCA gene mutations associated with harmful or suspected harmful after 3 chemotherapy (FDA also approved the gene Detection reagent) for patients with advanced ovarian cancer.\u003c\/p\u003e\u003cp\u003eOlaparib was approved by the FDA due to its objective response rate and response duration. Further of this indication\u003c\/p\u003e\u003cp\u003eApproval depends on the results of clinical benefit in confirmatory clinical trials.\u003c\/p\u003e\u003ch2\u003e\u003cspan id=\"Dose_and_administration_method\"\u003eDose and administration method\u003c\/span\u003e\u003c\/h2\u003e\u003col\u003e\u003cli\u003eMethod of administration\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\n\u003cli\u003eThe recommended dose is 400 mg twice a day, orally, either before or after meals.\u003c\/li\u003e\n\u003cli\u003eContinue to use until the disease progresses or unacceptable toxicity occurs.\u003c\/li\u003e\n\u003cli\u003eIf adverse reactions occur, consider discontinuing the medication or reducing the dose.\u003c\/li\u003e\n\u003cli\u003eFor patients with mild renal impairment (creatinine clearance (CLcr)=31-50mL\/min), the dose is reduced 300mg\/time.\u003c\/li\u003e\n\u003c\/ul\u003e\u003col start=\"2\"\u003e\u003cli\u003eDosage specifications\u003c\/li\u003e\u003c\/ol\u003e\u003cul\u003e\u003cli\u003eCapsule, 50mg.\u003c\/li\u003e\u003c\/ul\u003e\u003col start=\"3\"\u003e\u003cli\u003eContraindications: None.\u003c\/li\u003e\u003c\/ol\u003e\u003ch2\u003e\u003cspan id=\"Warnings_and_Precautions\"\u003eWarnings and Precautions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eMyelodysplastic syndrome\/acute myelogenous leukemia (MDS\/AML): The patient is taking European MDS\/AML appeared after Lini, and a large number of reports were fatal. Baseline monitoring of whole blood cells every month after treatment Cell count. Once diagnosed with MDS\/AML, Orini was stopped immediately.\u003c\/li\u003e\n\u003cli\u003ePneumonia: The patient develops pneumonia after taking Olini. In some cases, it is fatal. Once the lungs appear The treatment was discontinued for inflammatory symptoms, and Olini was discontinued after diagnosis.\u003c\/li\u003e\n\u003cli\u003eFetal-embryotoxicity: Olini can be fatal to the fetus. Advise women with reproductive capacity to suffer Patients take effective contraceptive measures during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Adverse_reactions\"\u003eAdverse reactions\u003c\/span\u003e\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eCommon adverse reactions (≥20%) in clinical trials include anemia, nausea, fatigue (including weakness), Vomiting, diarrhea, dizziness, indigestion, headache, loss of appetite, nasopharyngitis\/pharyngitis\/URI, cough, close Joint pain\/muscle pain, back pain, dermatitis\/rash, abdominal pain\/discomfort.\u003c\/li\u003e\n\u003cli\u003eCommon laboratory abnormalities (≥25%) include: creatinine, increase in average red blood cell volume; blood Globin, lymphocytes, absolute neutrophils, thrombocytopenia.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003e\u003cspan id=\"Storage_method\"\u003eStorage method\u003c\/span\u003e\u003c\/h2\u003e\u003cp\u003eStore between 20-25°C.\u003c\/p\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797953277995,"sku":"RL3020241020345","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-10-153-jpg.webp?v=1787022196"},{"product_id":"partruvix-ef-bc-88pamiparib-ef-bc-89","title":"PARTRUVIX（Pamiparib）","description":"\u003cp\u003ePamiparib  (BGB-290) is a drug used to treat various types of cancer. It's a PARP inhibitor, which means it prevents the repair of DNA breaks. \u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eSocazolimab \u003c\/span\u003esold under the brand name 百汇泽(PARTRUVIX)® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003e Based on the results from the pivotal phase II portion of a phase I\/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy.\u003c\/p\u003e","brand":"BeiGene Biotechnology, China","offers":[{"title":"Default Title","offer_id":44797957013547,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-144.png?v=1787022275"},{"product_id":"olanib-olaparib-inn-50-mg","title":"Olanib (Olaparib INN 50 mg )","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eOlanib 50 mg (Olaparib INN)\u003c\/strong\u003e is an oral anticancer medicine containing \u003cstrong\u003e50 mg of olaparib per hard capsule\u003c\/strong\u003e. It belongs to the \u003cstrong\u003ePARP inhibitor\u003c\/strong\u003e class and works by blocking PARP enzymes involved in DNA repair, making it particularly effective against certain cancers with \u003cstrong\u003eBRCA or other DNA-repair deficiencies\u003c\/strong\u003e. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eIt is used, depending on the cancer type and genetic status, in conditions such as \u003cstrong\u003eovarian, breast, pancreatic, and prostate cancers\u003c\/strong\u003e. Treatment should be prescribed and monitored by an oncology specialist. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e The 50-mg capsule is a specific formulation; olaparib tablet and capsule formulations are \u003cstrong\u003enot necessarily interchangeable milligram-for-milligram\u003c\/strong\u003e.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44889605046315,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/OlanibINN50mg.jpg?v=1787208626"},{"product_id":"niranib-niraparib-tosylate-monohydrate-equivalent-to-niraparib-100-mg","title":"Niranib (Niraparib Tosylate Monohydrate equivalent to Niraparib 100 Mg)","description":"\u003cp\u003e\u003cstrong\u003eNiranib 100 mg\u003c\/strong\u003e is an oral targeted anticancer medicine containing \u003cstrong\u003eniraparib\u003c\/strong\u003e, a PARP inhibitor. It works by blocking PARP enzymes involved in DNA repair, helping prevent the growth and survival of certain cancer cells. Niraparib is used in the treatment and maintenance treatment of certain \u003cstrong\u003eovarian, fallopian tube, and primary peritoneal cancers\u003c\/strong\u003e, according to the applicable indication and physician's assessment.\u003c\/p\u003e\n\u003cp\u003eNiranib (Niraparib Tosylate Monohydrate equivalent to Niraparib 100 mg) is an oral PARP inhibitor used in the treatment of certain ovarian, fallopian tube, and primary peritoneal cancers.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44890147225643,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Niranib.jpg?v=1787226058"},{"product_id":"paribac-100-niraparib","title":"Paribac 100 (Niraparib)","description":"\u003cp\u003e\u003cstrong\u003eParibac 100 (Niraparib)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003eniraparib\u003c\/strong\u003e\u003cspan\u003e, a PARP inhibitor that works by blocking enzymes involved in DNA repair, helping prevent certain cancer cells from repairing damaged DNA and continuing to grow. It is used primarily in the treatment and maintenance therapy of certain \u003c\/span\u003e\u003cstrong\u003eovarian, fallopian tube, and primary peritoneal cancers\u003c\/strong\u003e\u003cspan\u003e, particularly in patients with specific disease characteristics. Paribac 100 contains \u003c\/span\u003e\u003cstrong\u003e100 mg of niraparib\u003c\/strong\u003e\u003cspan\u003e and is supplied in a \u003c\/span\u003e\u003cstrong\u003e30-capsule pack\u003c\/strong\u003e\u003cspan\u003e.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896160776235,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/paribac-100-161.jpg?v=1787298706"},{"product_id":"paribac-niraparib","title":"Paribac (Niraparib)","description":"\u003cp\u003e\u003cstrong\u003eParibac (Niraparib)\u003c\/strong\u003e\u003cspan\u003e is an oral targeted anti-cancer medicine containing \u003c\/span\u003e\u003cstrong\u003eniraparib\u003c\/strong\u003e\u003cspan\u003e, a PARP inhibitor that blocks enzymes involved in DNA repair, helping prevent certain cancer cells from repairing damaged DNA and continuing to grow. It is primarily used as maintenance treatment for certain \u003c\/span\u003e\u003cstrong\u003eovarian, fallopian tube, and primary peritoneal cancers\u003c\/strong\u003e\u003cspan\u003e. Paribac is available in \u003c\/span\u003e\u003cstrong\u003ecapsule form with a 30-capsule pack size\u003c\/strong\u003e\u003cspan\u003e. \u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":44896674644011,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/paribac-294.png?v=1787308207"},{"product_id":"olanib-150olaparib-inn-150-mg","title":"Olanib 150(Olaparib INN 150 mg)","description":"\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003e\u003cstrong\u003eOlanib 150\u003c\/strong\u003e contains \u003cstrong\u003eolaparib 150 mg\u003c\/strong\u003e and is manufactured by Everest Pharmaceuticals in Bangladesh. It is an \u003cstrong\u003eoral targeted cancer medicine\u003c\/strong\u003e belonging to the \u003cstrong\u003ePARP inhibitor\u003c\/strong\u003e class.\u003c\/p\u003e\n\u003cp class=\"PDq2pG_selectionAnchorContainer\"\u003eOlaparib works by blocking PARP proteins involved in DNA repair. This can make it difficult for certain cancer cells—especially those with \u003cstrong\u003eBRCA or other DNA-repair abnormalities\u003c\/strong\u003e—to survive. It is used for selected patients with \u003cstrong\u003eovarian, breast, pancreatic, and prostate cancers\u003c\/strong\u003e, depending on the cancer type and genetic\/biomarker results. \u003cspan class=\"contents\"\u003e\u003cspan class=\"\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan class=\"PDq2pG_selectionAnchor\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImportant:\u003c\/strong\u003e Olanib 150 should be taken \u003cstrong\u003eonly under an oncologist's prescription\u003c\/strong\u003e. The 150 mg tablet is not necessarily the dose every patient should take; the usual tablet regimen for many indications is \u003cstrong\u003e300 mg twice daily\u003c\/strong\u003e, but the correct dose depends on the patient and cancer.\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45022305976363,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/Olanib150_4d868bfe-e2d1-470c-878c-3f2e917cc2fa.jpg?v=1787512662"}],"url":"https:\/\/xomeds.com\/collections\/ovarian-cancer.oembed","provider":"XOMEDS","version":"1.0","type":"link"}